Fig. 3: Prognostic power of tumor differentiation (TD) and basal-luminal gene expression signatures. | Communications Biology

Fig. 3: Prognostic power of tumor differentiation (TD) and basal-luminal gene expression signatures.

From: Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy

Fig. 3

a Heatmaps of gene expression of 42 basal-luminal genes (including 18 TD genes) in the TCGA (n = 388) and IMvigor210 (n = 348) cohorts. b, c Patient overall survival stratified by the basal and luminal subtypes defined by the 42 basal-luminal genes (b), and by the basal and differentiated subtypes defined by the 18 TD genes (c) in the IMvigor210 cohort. d Heatmaps of G3 (MTAP/CDKN2A/2B) expression in the basal and luminal/differentiated subtypes in the TCGA and IMvigor210 cohorts, which were further divided into relatively G3 high expression (G3High) or low expression (G3Low) subgroup. On the top panel, the copy number data of chr9 p21.3 are aligned with the G3 expression data in the TCGA cohort, indicating a high concordance between copy number and gene expression. e Overall survival stratified by the G3High and G3Low groups in the TCGA cohort (375 non-NAC patients). f Overall survival stratified by the Basal_G3High, Basal_G3Low, Luminal_G3High, and Lumina_G3Low groups in the TCGA cohort (375 non-NAC patients). Log-rank test was used to compare subtype-specific survival curves.

Back to article page